Top Pharma Companies Not Following Current Good Manufacturing Processes: Angiotensin II Receptor Blockers With Carcinogenic Impurities: A Threat to Global Public Health

NeuroPharmac Journal
doi 10.37881/1.432
Full Text
Abstract

Available in full text

Date
Authors
Publisher

NeuroPharmac Journal

Related search

Plasmodium Knowlesi as a Threat to Global Public Health

Korean Journal of Parasitology
ParasitologyInfectious Diseases
2015English

Health as a Global Public Good

1999English

The Effect of Angiotensin II Receptor Blockers on Hyperuricemia

Therapeutic Advances in Chronic Disease
Medicine
2015English

Combining Angiotensin-Receptor Blockers With Angiotensin-Converting-Enzyme Inhibitors

CMAJ
Medicine
2011English

Angiotensin Receptor Blockers (ARBs)

CMAJ
Medicine
2011English

Angiotensin II Type 1 Receptor Blockers Do Not Promote Coronary Collateral Circulation in Patients With Coronary Artery Disease

Hypertension Research
Internal MedicineCardiovascular MedicinePhysiologyCardiology
2006English

Letter: Sprue-Like Enteropathy Associated With Angiotensin II Receptor Blockers Other Than Olmesartan

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Polymorphisms of the Angiotensin II Type 1 Receptor Gene Affect Antihypertensive Response to Angiotensin Receptor Blockers in Hypertensive Chinese

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2013English

Higher Small Arterial Elasticity in Hypertensive Patients Treated With Angiotensin II Receptor Blockers

Hypertension Research
Internal MedicineCardiovascular MedicinePhysiologyCardiology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy